T-DXd Active in Many Solid Tumors; 'Shift in Thinking'

The antibody-drug conjugate trastuzumab-deruxtecan was associated with high objective response rates among patients with a range of HER2-expressing solid tumors.
Medscape Medical News

source https://www.medscape.com/viewarticle/992819?src=rss